The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1500
August 1, 2016
View Complete Issue         Table of Contents 2019 
Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
August 1, 2016 (Issue: 1500)
The FDA has approved venetoclax (Venclexta – Abbvie/Genentech), an oral selective BCL-2 inhibitor, for treatment of chronic lymphocytic leukemia (CLL) in patients with a 17p deletion who have received at least one prior therapy. The 17p...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
Article code: 1500d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.